Chromatographic stationary phase

Information

  • Patent Application
  • 20070084774
  • Publication Number
    20070084774
  • Date Filed
    October 18, 2006
    19 years ago
  • Date Published
    April 19, 2007
    18 years ago
Abstract
A chromatographic stationary phase comprises a solid support having bonded thereto a mixture of two different silyl groups I and II. The ratio of the silyl groups I and II ranges from 99:1 to 1:99. Chromatographic stationary phases according to the present invention are more resistant to phase collapse than prior art stationary phases.
Description
BACKGROUND

Chromatography, for example liquid chromatography (LC), gas chromatography (GC) or supercritical fluid chromatography (SFC), is employed in both analytical and preparative methods to separate one or more species, e.g. chemical compounds, present in a carrier phase from the remaining species in the carrier phase. Chromatography is also employed, in a manner independent of separation of chemical species, as a method for analyzing purity of a chemical species, and/or as a means of characterizing a single chemical species. Characterization of a chemical species may comprise data, for example, a retention time for a particular chemical compound, when it is eluted through a particular chromatography column using specified conditions, e.g., carrier phase composition, flow rate, temperature, etc.


The carrier phase, often termed the “mobile phase,” for reversed phase (RP) LC typically comprises water and one or more water-miscible organic solvents, for example, acetonitrile or methanol. The carrier phase for SFC typically comprises supercritical carbon dioxide and, optionally, one or more organic solvents that are miscible therewith, e.g., an alcohol. The species typically form a solution with the carrier phase. The carrier phase is typically passed through a stationary phase.


The rate at which a particular species in a carrier phase passes through a stationary phase depends upon the affinity of the species for the stationary phase.


Species having a higher affinity for the stationary phase pass through at slower rates relative to species having lower affinity for the stationary phase.


Affinity of a species for a stationary phase results primarily from interaction of the species with chemical groups present on the stationary phase. Chemical groups may be provided on the stationary phase by reacting a surface-modifying reagent with a substrate, such as a silica substrate. Chemical groups attached to the surface of the substrate can modulate the rate at which different species pass through the chromatography column. Surface-modifying agents may be employed to install desired chemical groups onto the stationary phase. For example, a suitable stationary phase for separating an anionic species from a cationic species may be prepared using a surface-modifying reagent to attach a cationic chemical group to a substrate surface thereby forming a stationary phase having cationic groups.


For polar species, a carrier phase comprising a high percentage of water, for example, greater than 95% water may be useful to effect separation of one or more of the species. In addition, some chromatographic methods make use of so-called gradients, in which the composition of the carrier phase may transition from a primarily aqueous to a primarily organic composition, or vice versa, over the course of an analysis. In either case, highly aqueous conditions routinely cause conventional C8 and C18 stationary phases to demonstrate diminished retention properties due to the hydrophobic nature of the C8 and C18 alkyl groups attached to the substrate. This loss in retention properties is commonly due to the phenomenon of hydrophobic phase collapse (hereinafter “phase collapse”).


Phase collapse is believed to occur when the carbon chains of a stationary phase, such as C8 or C18 gradually cluster together when a carrier phase comprising a high percentage of water is passed through the stationary phase.


Phase collapse significantly decreases the interaction between the stationary phase and the carrier phase. Carrier phases containing a high water percentage are also thought to be expelled from pores in the stationary phase, due to repulsion between the polar carrier phase and the hydrophobic stationary phase surface. The expulsion from pores is accelerated when pressure in a chromatography column drops, e.g., when the system pump, that supplies a flow of the carrier phase to the column, is stopped.


Previous solutions to this problem have included the incorporation of polar groups into organosilane moieties attached to the substrate in addition to the non-polar C8 or C18 groups.


Published patent application US2004/0262224, discloses a solution to the problem of phase collapse which comprises a low density bonding of the hydrophobic bonded phase to the stationary phase substrate.


Considerable research has been directed toward new stationary phase compositions for use in chromatography. There had remained, however, a need to provide such stationary phase compositions for chromatography which provide useful separation characteristics for particular types of species mixtures and also for broad application to chromatographic separations.


SUMMARY

According to an embodiment of the invention, there is provided a chromatographic stationary phase composition comprising a solid support, ⊕, having bonded thereto at least one silyl moiety according to Formula I:

—O—Si(R1)n(X1)m  Formula I

and at least one different silyl moiety according to Formula II:

—O—Si(R2)n(X2)m  Formula II

wherein:


X1 and X2 are independently —(C1-C6)hydrocarbyl;


—O—Si represents an oxygen bond between the silane and the solid support;


n is 1;


m is 2; and


R1 is —(C2-C6)hydrocarbyl; and


R2 is —(C8-C30)hydrocarbyl.


The molar ratio of the silyl moiety of Formula I to the silyl moiety of Formula II in the composition is from 1:99 to 99:1.


The density of the combined silyl moieties of Formula I and Formula II on the solid support is from about 1.0 μmol/m2 to about 4.0 μmol/m2.


According to another embodiment of the invention is provided a method for producing a chromatographic stationary phase comprising reacting a solid support, ⊕, having reactive silanol groups thereon with a first silane compound according to Formula III:

Si(R1)n(X1)m(L)g  Formula III

and a second different silane compound according to Formula IV:

Si(R2)n(X2)m(L)g  Formula IV

wherein:


R1, R2, X, n, m are as defined above; and


L is a reactive chemical group and g is 1.


The first silane and second silane are reacted with the solid support either concurrently or sequentially. The molar ratio of first silane to second silane reacted with the solid support is from 1:99 to 99:1. The chromatographic stationary phase recovered from the process comprises a solid support, ⊕, having bonded thereto a first silyl moiety according to Formula I and a second silyl moiety according to Formula II as defined above.


According to a further embodiment of the invention is provided a chromatographic method comprising


(a) providing a column packed with a chromatographic stationary phase comprising a solid support, ⊕, having bonded thereto at least one silyl moiety according to Formula I as defined above and at least one silyl moiety according to Formula II as defined above;


(b) providing a carrier phase;


(c) passing the carrier phase through the column; and


(d) injecting the mixture into the carrier phase at a point prior to the carrier phase entering the column;


wherein the carrier phase is capable of eluting at least one species contained in the sample through the column.


Additional aspects, advantages and novel features of the invention will be set forth in part in the Description, and the Examples which follow, all of which are intended to be for illustrative purposes only, and not intended in any way to limit the invention, and in part, will become apparent to those skilled in the art on examination of the following, or may be learned by practice of the invention.







DETAILED DESCRIPTION

A. Definitions


The term “alkyl”, by itself, or as part of another substituent, e.g., cyanooalkyl or aminoalkyl, means a hydrocarbyl group, which is a saturated hydrocarbon radical having the number of carbon atoms designated (i.e., C1-C6 alkyl means the group contains one, two, three, four, five or six carbon atoms) and includes straight, branched chain, cyclic and polycyclic groups. Examples include: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, cyclohexyl, decyl, dodecyl, tetradecyl, octadecyl, norbornyl, and cyclopropylmethyl. Alkyl groups include, for example, —(C1-C40)alkyl, —(C1-C6)alkyl, —(C3-C20) alkyl and —(C6-C40)cycloalkyl.


The term “saturated,” with respect to an alkyl group means that all of the carbon-carbon bonds in the alkyl group are carbon-carbon single bonds.


The term “hydrocarbyl” refers to any moiety comprising only hydrogen and carbon atoms. Hydrocarbyl groups include saturated, e.g., alkyl groups, unsaturated groups, e.g., alkenes and alkynes, aromatic groups, e.g., phenyl and naphthyl and mixtures thereof. Hydrocarbyl groups include, for example, (C1-C40)hydrocarbyl, (C6-C40)hydrocarbyl, and —(C6-C40)alkyl.


The term “alkylene,” by itself or as part of another substituent, means a saturated hydrocarbylene radical.


The term “hydrocarbylene” by itself or as part of another substituent means a divalent straight, branched or cyclic chain hydrocarbon radical having the designated number of carbons. For example, the expression “(C1-C4)hydrocarbylene-R” includes one-, two-, three- and four-carbon divalent hydrocarbon groups. A substitution of a group, such as R, on a hydrocarbylene, may be at any substitutable carbon.


The term “substituted” means that a hydrogen atom attached to a group, e.g., a hydrocarbyl group, has been replaced by another atom, e.g. Cl, or group of atoms, e.g. CH3. For aryl and heteroaryl groups, the term “substituted” refers to any level of substitution, for example, mono-, di, tri-, tetra-, or penta-substitution.


Substituents are independently selected, and substitution may be at any position that is chemically and sterically accessible.


The term “aryl” employed alone or in combination with other terms, means a hydrocarbyl group which is a carbocyclic aromatic group containing one or more rings (typically one, two or three rings), wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples include phenyl, anthracyl and naphthyl.


The term “—(Cu-Cv)alkylene-(Cx-Cy)aryl-” wherein u, v, x and y are integers and u<v and x<y, means a radical wherein a carbon alkylene chain, having from u to v carbon atoms, is attached to an aryl group having from x to y carbon atoms.


Examples include, —CH2CH2-phenyl, CH2-phenyl and CH2-naphthyl. Alkylene groups for “—(Cu-Cv)alkylene-(Cx-Cy)aryl-” include, for example, —CH2—, —CH2CH2— and —CH(CH3)—. The term “substituted —(Cu-Cv)alkyl-(Cx-cy)aryl-” means a group as defined above in which the aryl group is substituted.


The term “cycloalkyl” refers to ring-containing alkyl radicals. Cycloalkyl groups may contain, for example, 1, 2 or 3 rings. For cycloalkyl groups containing more than one ring, i.e., polycyclic cycloalkyl groups, the rings may be fused, i.e., two rings share two or more adjacent ring atoms and the bonds connecting the two or more shared ring atoms, spiro-fused, i.e., two rings share one ring atom, or the rings may be connected in a pendent manner, i.e. one atom of one ring is bonded to one atom of a second ring, wherein the connecting bond may be a single bond or a double bond. Examples of a fused ring sharing two ring atoms (a), a fused ring sharing more than two ring atoms (b), a spiro-fused ring (c) and rings connected in a pendant manner (d) are depicted in Scheme 1.
embedded image


Examples of cycloalkyl groups include cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, cyclooctylethyl, norbornyl, decahydronaphthyl and tetradecahydroanthryl.


The expression, “reactive chemical group” refers to a chemical group in a compound which group is, for example, nucleophilic or electrophilic, or a substrate for electrophilic addition reaction, such that the reactive chemical group is the chemical group directly involved in bond making or bond breaking in a chemical reaction of the compound. Examples of nucleophilic reactive chemical groups include primary and secondary amino groups, alcohol —OH groups, and thiol —SH groups. Examples of electrophilic reactive chemical groups include leaving groups. An example of a group that is a substrate for electrophilic addition is an olefin group such as a vinyl group.


The expression “leaving group” refers to the chemical group that is displaced in a substitution or elimination reaction. Examples include halogen atoms, such as —Cl and —Br, and sulfonate moieties, such as mesyl, tosyl, nosyl, and trifyl.


The term “metal” refers to an element that is lustrous, ductile and generally electropositive, i.e., forms compounds in positive oxidation states, and that is a conductor of heat and electricity as a result of having an incompletely filled valence shell. The term, “metal oxide” refers to a chemical compound of oxygen with a metal, for example, tin oxide. The term “metal oxide” is inclusive of metal oxides that have been treated so as to provide particular functional groups on the surface of the metal oxide.


The term “metalloid” refers to an element, for example zirconium, or silicon which demonstrates properties which are intermediate between the properties of typical metals and typical nonmetals, i.e., has physical appearance and properties of a metal (as defined above), but behaves chemically as a non-metal. Elements classified as metalloids are in the periodic table in a diagonal block separating metals from nonmetals, and include, for example silicon, boron, arsenic, bismuth, germanium, antimony, and tellurium. The term, “metalloid oxide” refers to a chemical compound of oxygen with a metalloid, for example, silicon dioxide. The term “metalloid oxide” is inclusive of metalloid oxides that have been treated so as to provide particular functional groups on the surface of the metalloid oxide, for example, Si—OH, Si—H or Si—Cl groups.


B. Silyl Groups of Formulae I and II


In silyl groups of Formulae I or II, X may be, for example, —(C1-C6)alkyl. According to an embodiment of the invention, one of R1 is a straight chain or branched chain alkyl group (C2 to C6) and R2 is a straight chain or branched chain alkyl group (C8 to C30), which may include one or more cycloalkyl groups. Combinations of R1/R2 may include for example: C2/C8, C3/C8, C4/C8, C5/C6, C2/18, C3/C18, C4/C18, C5/C18, C6/C18, C2/C30, C3/C30, C4/C30, C5/C30 and C6/C30.


R2 may independently comprise, for example, a C4-C24 straight chain alkyl group to which is bonded at least one cyclohexyl group, for example, one, two three or four cyclohexyl groups, wherein the at least one cyclohexyl group is optionally substituted by one or two substituents which are —(C1-C4)alkyl and which substituents may be the same or different.


According an embodiment of the invention, R2 comprises, for example, a substituted or unsubstituted (C6-C14) aryl group or a (C6-C30) cyclic alkyl group, which cyclic alkyl group may be a monocyclic alkyl group or a polycyclic alkyl group;


A cyclic alkyl R2 group may be selected, for example, from the group consisting of cyclodecyl, cyclododecyl, cyclotetradecyl, cyclooctadecyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, 4-t-butylcyclohexyl, 3,5-dimethylcyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 2,2-dicyclohexylethyl, 4-(cyclohexyl)cyclohexyl, 4-((4-cyclohexyl)cyclohexyl)cyclohexyl, 1-decahydronaphthyl, 2-decahydronaphthyl, 1-tetradecahydroanthryl, 2-tetradecahydroanthryl, 10-tetradecahydroanthryl, octahydro-1H-indenyl, 4-cyclohexylidenecyclohexyl and 4,4-(spiro-cyclohexyl)cyclohexyl.


C. The Substrate


Substrates useful in the invention have a surface comprising chemical groups that are capable of reacting with a surface modifying reagent. For example, metalloid oxides, such as silica or alumina, may be suitably chemically prepared, e.g., by hydrolysis, such that surface —OH groups are provided for reaction with a surface modifying reagent, for example, a silane reagent comprising a leaving group, for example a Si—Cl group.


The substrate surface may alternatively be derivatized to provide chemical groups other than an —OH group, which groups are reactive toward surface-modifying silane reagents that have a reactive moiety other than a leaving group. For example, the surface of silica substrate may be halogenated with a halogenating reagent, e.g., a chlorinating agent, for example, silicon tetrachloride or thionyl chloride. The resulting halogenated substrate surface, containing reactive Si—X groups, wherein X is a halogen, may then be reacted with silane reagents containing, for example, Si—OH groups to prepare the stationary phase compositions according to the invention.


The silica surface may alternatively be derivatized to provide —Si—H groups. Such Si—H groups may be reacted, for example, with an olefin, such as a vinyl group in a hydrosilation reaction.


The substrate comprises, for example, a material selected from the group consisting of silica, hybrid silica, zirconia, titania, chromia, alumina and tin oxide.


According to an embodiment of the invention, a substrate comprises particles of the metal oxide or metalloid oxide, for example, particles of silica. The substrate particles may comprise, for example, microspheres, for example, silica microspheres.


For the practice of the invention, for use as chromatography substrates, microspheres, such as silica microspheres, may have an average diameter ranging from about 0.5 to about 200 microns, or alternatively, from about 0.5 to about 50 microns, or alternatively, from about 1 to about 30 microns, or alternatively, from about 1 to about 15 microns. According to one embodiment of the invention, the microspheres have an average diameter of from about 0.5 to 5 microns. According to an alternative embodiment, the microspheres have an average diameter of from about 5 to about 200 microns. The expression “average diameter” means the statistical average of the spherical diameters of the microspheres.


Microspheres, such as silica microspheres, useful as substrates in the practice of the invention may be porous or non-porous. According to an embodiment the microspheres may have a surface area of from about 60 m2/g to about 500 m2/g, or from 300 m2/g to 400 m2/g. Porous microspheres may have controlled pore dimensions and a relatively large pore volume. According to an embodiment of the invention the microspheres may have an average pore diameter of from about 60 Å to about 1000 Å. According to an embodiment of the invention the average pore diameter may be from about 80 Å to about 200 Å. According to an embodiment of the invention the average pore diameter may range from about 100 Å to about 200 Å. According to another embodiment of the invention the average pore diameter may from about 100 Å to about 130 Å.


According to an embodiment of the invention, the microspheres may be a hybrid such as silica/zirconia, silica/titania or silica/alumina for example. Hybrid silicas include materials where a portion of the Si atoms, or SiO groups have been replaced by other metal or metalloid atoms, such as W, Mg, Al, Zr, B or Ge. Alternatively, in hybrid silica, a portion of the Si—O bonds have been replaced by other moieties, such as hydrocarbyl or O-hydrocarbyl groups, hydrogen or other species, such as phosphorous. For example, a hybrid silica may include a fraction having the formula Si—O—Si—Y—Si—O or Si—OSi(Y)—O, where Y represents a metal, metalloid, hydrocarbyl or other species.


The size and shape of substrates useful in the practice of the invention are variable. According to an embodiment of the invention, a substrate may comprise a solid material coated with a layer of a suitable metal oxide or metalloid oxide, for example, silica, which is capable of reacting with a suitable silane reagent. The substrate may be in the form of different shapes, such as spheres, irregularly shaped articles, rods, plates, films, sheets, fibers, or other massive irregularly shaped objects. For example, titania may be coated with a thin layer of silica, for example according to the method described by Iber. See, Iber, “The Chemistry of Silica,” John Wiley and Sons, New York, 1979, p. 86; the entire disclosure of which is incorporated herein by reference. This layer of silica may be prepared, e.g., by hydrolysis, and reacted with a suitable silane reagent.


When the compositions disclosed herein are used in chromatography, the composition may be, for example, packed in a chromatography column or deposited onto a chromatography plate.


D. Preparation of Compositions


The preparation of stationary phase compositions by reaction of a individual silanes with a substrate is known. A general discussion of the reaction of individual silanes with the surface of silica-based support materials is provided in “An Introduction to Modern Liquid Chromatography,” L. R. Snyder and J. J. Kirkland, Chapter 7, John Wiley and Sons, NY, N.Y. (1979) the entire disclosure of which is incorporated herein by reference. The reaction of individual silanes with porous silica is disclosed in “Porous Silica,” K. K. Unger, p. 108, Elsevier Scientific Publishing Co., NY, N.Y. (1979) the entire disclosure of which is incorporated herein by reference. A description of reactions of individual silanes with a variety of support materials is provided in “Chemistry and Technology of Silicones,” W. Noll, Academic Press, NY, N.Y. (1968) the entire disclosure of which is incorporated herein by reference.


The reactive group L may be, for example, a leaving group. When L is a leaving group, L may be independently selected, for example, from the group consisting of halogen, for example, —F, —Cl and —Br; —O(C1-C6)alkyl, for example, —OCH3 and —OC2H5; and —N((C1-C3)alkyl)2, for example —N(CH3)2 and —N(C2H5)2.


The silane reagent, such as octadecyldimethylsilylchloride, which has one leaving group, i.e. the —Cl leaving group, reacts to bond to the substrate, ⊕, as shown in Scheme 2.
embedded image


The process, according to the present invention, of preparing a stationary phase composition may comprise a single step reaction of a mixture of one or more silanes of Formula III and one or more silanes of Formula IV with a suitable substrate. Typically, the reaction may be performed in a suitable organic solvent or solvent mixture, for example, toluene, xylene, or mesitylene or a mixture thereof. The reaction may, for example, be performed at an elevated temperature, for example, from about 50° C. up to the reflux temperature of the solvent or solvent mixture. The relative amounts of each of the silanes which are incorporated into the prepared stationary phase composition may be controlled, for example by controlling the ratio of the different silanes of Formulae III and IV that are added to the reaction.


Silanes of Formulae III and IV may be used in the process of the invention in any proportion from about 1% of III and 99% of IV to about 99% III and 1% IV, based on the total amount of silane reagents according to Formulae III and IV in the liquid medium. Thus, processes for preparing a stationary phase composition according to the invention comprise mixtures of reagents of Formulae III and IV which may be in a ratio of Formula III silanes to Formula IV silanes of, for example, 1%-99%, 5% to 95%, 10% to 90%, 15% to 85%, 20% to 80%, 25% to 75%, 30% to 70%, 35% to 65%; 40% to 60%, 45% to 55%, 50% to 50%, 55% to 45%, 60% to 40%, 65% to 35%, 70% to 30%, 75% to 25%, 80% to 20%, 85% to 15%, 90% to 10%, 95%-5% or 99% to 1%.


According to an embodiment of the current invention, in addition to controlling the ratio of the two silanes reacted with the solid support, the amount of each silane of Formula III and Formula IV reacted with the solid support are calculated to obtain a specific density of the bonded phase bonded to the solid support.


In published U.S. patent Application US2004/0262224, which is hereby incorporated by reference in its entirety, it is disclosed that low density bonding of a hydrophobic bonded phase to a substrate results in the reduction or elimination of phase collapse. U.S. patent Application US2004/0262224 dislcoses this result for solid supports having a single silyl group, such as a C8 or C18 silyl group bonded thereto. According to US2004/0262224, low density bonding includes bonding densities of a hydrophobic bonded phase of from about 1.0 μmol/m2 to about 3.4 μmol/m2.


According to an embodiment of the current invention, the combined bonding density of the silyl group according to Formula I and the silyl group according to Formula II is from about 1.0 μmol/m2 to about 4.0 μmol/m2. According to another embodiment of the current invention, the combined bonding density of the silyl group according to Formula I and the silyl group according to Formula II is from about 1.0 μmol/m2 to about 3.0 μmol/m2. According to another embodiment of the current invention, the combined bonding density of the silyl group according to Formula I and the silyl group according to Formula II is from about 1.0 μmol/m2 to about 2.5 μmol/m2. According to another embodiment of the current invention, the combined bonding density of the silyl group according to Formula I and the silyl group according to Formula II is less than about 2.0 μmol/m2. According to another embodiment of the current invention, the combined bonding density of the silyl group according to Formula I and the silyl group according to Formula II is less than about 1.5 μmol/m2.


The relative amounts of each of the silyl groups which are incorporated into the prepared stationary phase will be influenced by the average pore size of the substrate, when a porous substrate is used. According to an embodiment of the invention the larger the average pore size of the porous substrate the more of the silyl group according to Formula IV may be incorporated into the prepared stationary phase.


The relative amounts of each of the silyl groups which are incorporated into the prepared stationary phase composition may also be influenced by differences in reactivity of the different silane reagents of Formulae III and IV. Such differences in reactivity may result due to the presence of different R1, R2 or X groups on the silane, for example due to steric bulk. Reactivity of silanes that contain a particular R1 and X groups or R2 and X groups, may also be modulated by selection of the reactive chemical group L.


Novel compositions according to the present invention may alternatively be prepared by a multi-step reaction, wherein the substrate may be reacted sequentially with different single silane reagents according to Formulae III and IV. Typically, each of the sequential reactions may be performed in a suitable organic solvent or solvent mixture, for example, toluene, xylene, or mesitylene and mixtures thereof. Each reaction is typically performed at an elevated temperature, for example, from about 50° C. up to the reflux temperature of the solvent or solvent mixture. The sequential reactions with different silane reagents may be performed with or without isolation of the intermediate product after each of the sequential reactions. The relative amounts of each of the silanes which are incorporated into the prepared stationary phase composition may be controlled by controlling the amount of each reagent that is incorporated into the substrate during each of the sequential steps. The amount of each reagent that is incorporated into the substrate during a reaction may be controlled, for example, by controlling the stoichiometry of the reaction, by controlling the reaction conditions, such as reaction time, reaction temperature and concentration of reagents, i.e. by using either an excess or deficit of the calculated stoichiometric amount. The amount of each reagent incorporated may also be controlled by selection of silane reagent of Formulae III or IV having a suitable reactive moiety—L, or by selection of any combination factors affecting the amount of the silane reagent incorporated into the substrate. When a multi-step preparation is used, the reaction conditions, such as stoichiometry, may be suitably restricted to limit the incorporation of the silyl group for all but the last silane reagent to be reacted. For the last silane to be reacted, the reaction conditions, such as stoichiometry, may be suitably controlled to react as much as possible of the remaining reactive groups on the substrate surface. The appropriate reaction conditions for each silane and combination of silanes may be readily ascertained through routine experimentation.


For example, the first silane reagent to be reacted with the substrate may be reacted, for example, in an amount that is calculated to form covalent bonds to a limited percentage, for example 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, of the reactive groups, for example silanol groups, that are available on the substrate surface. For example, in the case of fully hydroxylated silica surfaces, about 8 micromol/m2 of potentially reactive silanol groups are present on the surface. The number of available silanol groups is one factor that may be considered in calculating reaction stoichiometry. For porous substrates, the average pore diameter is a factor that may be considered in calculating reaction stoichiometry. Another factor which may affect the reaction is the variable steric effect associated with different R1, R2 and X groups in the silanes of Formulae III and IV employed in the preparation of compositions of the invention. For larger and/or more sterically demanding silanes, fewer of the total available silanol groups may physically be reacted. Even for a smaller silane reactant, all of these silanol groups may not be reacted. For example, for chlorotriisopropylsilane reacted individually with a silane substrate, it has been estimated that about 1.3 micromol/m2 of silane can be covalently bonded to the substrate surface. See, U.S. Pat. No. 4,705,725, the entire contents of which are incorporated herein by reference. For sterically larger silanes, even lower maximum numbers of the available silanol groups may effectively react to form covalent bonds with the silane.


The product composition obtained from either the single step or the multi-step preparation may optionally further be reacted with an end-capping reagent. The end-capping reagent may be a relatively small silane reagent, for example, LSiRe3, wherein L is a reactive chemical group such as a —Cl leaving group; and Re is a —(C1-C4) alkyl group. The endcapping reagent serves to react with reactive groups on the substrate surface, e.g., silanol groups on a silica substrate, that remain unreacted with a silane according to Formula III or IV after the reaction therewith is completed.


Compositions according to the invention comprise a silyl group according to Formula I in any proportion from about 1% up to about 99% based on the total amount of silyl groups according to Formulae I and II which are bonded to the composition according to the invention. Likewise, compositions according to the invention comprise a silyl group according to Formula II in any proportion from about 1% up to about 99% based on the total amount of silyl groups according to Formulae I and II which are bonded to the composition according to the invention. Thus, compositions according to the invention comprise silyl groups having a ratio of Formula I silyl groups to Formula II silyl groups of, for example, 1% to 99%, 5% to 95%, 10% to 90%, 15% to 85%, 20% to 80%, 25% to 75%, 30% to 70%, 35% to 65%; 40% to 60%, 45% to 55%, 50% to 50%, 55% to 45%, 60% to 40%, 65% to 35%, 70% to 30%, 75% to 25%, 80% to 20%, 85% to 15%, 90% to 10%, 95%-5%, or 99% to 1%.


E. Chromatography Tools Containing the Composition


The composition according to the present invention may be employed in methods of separating chemical species by chromatography. For use in chromatography, the composition according to the invention, in a particulate form, may be, for example, packed into a chromatography column. Chromatography columns are produced in a variety of dimensions, which are based on the application that the particular column is used for. According to an embodiment of the invention, column dimension may range from about 0.1 mm to about 21.2 mm in diameter and from about 5 mm to about 250 mm in length. According to an embodiment of the invention column diameters may be from about 0.1 mm to about 9.4 mm According to an embodiment of the invention column diameters may be from about 0.1 mm to about 4.6 mm. According to an embodiment of the invention column lengths range from 5 to 250 mm. According to an embodiment of the invention column lengths may also range from 20 mm to 150 mm. The chromatography column containing a composition according to an embodiment of the invention may be operably connected to a reservoir containing a suitable carrier phase, and to a pump, for example, a mechanical or syringe pump, capable of pumping the carrier phase through the chromatography column, and to an injector capable of introducing one or more chemical species into the chromatography column. According to an embodiment of the invention the carrier phase may be pumped through the column at a rate of from about 0.1 mL/min. to about 20 mL/min. According to an embodiment of the invention, flow rates may range from 0.1 mL/min. to 5 mL/min., or 5 mL/min to 20 mL/min. According to an embodiment of the invention flow rates may also range from 1 mL/min. to 2 mL/min., or from 10 mL/min to 15 mL/min. The chromatography column containing a composition according to the invention may further be operably connected to a detector, for example, an ultraviolet spectrophotometer, capable of detecting and optionally analyzing separated chemical species that are eluted from the chromatography column. The chromatography column containing a composition according to the invention may further be operably connected to a fraction collector capable of collecting the carrier phase containing separated species in a plurality of separate containers such that the separated species may be handled separately.


The composition according to the invention, in a particulate form, may alternately be deposited onto a chromatography plate, e.g., a thin layer chromatography plate or preparative thin layer chromatography plate. A chromatography plate comprises a layer of a material, for example, glass or a polymer film, on which is deposited a chromatographic stationary phase composition.


A chromatography plate containing a composition according to the invention may be operably connected to a reservoir of a suitable mobile phase and to an injector capable of introducing chemical species onto the chromatography plate.


The composition according to the invention may alternately be employed in solid phase extraction (SPE) processes. For use in SPE processes, compositions according to the invention may be provided, for example, in an SPE cartridge. The expression “solid phase extraction cartridge” is understood to include housings of various shapes, sizes and configurations which contain one or more stationary phase compositions according to the invention. SPE cartridges thus include, for example, cylindrical columns and disks. SPE cartridges include cartridges that are designed as disposable units and cartridges designed for repeated use. SPE cartridges include single cartridges and arrays of cartridges, for example ninety-six well plates. Passage of a carrier phase through a SPE cartridge may be performed, for example by employing a solvent pump to push the carrier phase through the SPE cartridge, or by application of vacuum to pull the carrier phase through the cartridge. The stationary phase compositions of the invention, provided in a SPE cartridge, may be provided in amounts, for example from about 25 mg to about 100 g per cartridge.


The instrumentation and techniques for using compositions according to the invention for chromatographic separations, including high performance liquid chromatography (HPLC), thin layer chromatography (TLC), flash chromatography, solid phase extraction and other forms of chromatographic separation can be understood and employed by those skilled in the art.


The practice of the invention is illustrated by the following non-limiting examples.


EXAMPLES

General Procedure:


Step A: Preparation of a Silica Substrate


Porous silica particles (13 g, 5 micron diameter, 80 angstrom pore size) are obtained from Agilent Technologies, Inc. (Palo Alto Calif.). The silica particles are then treated according to the method of J. J. Kirkland and J. Kohler U.S. Pat. No. 4,874,518, the entire disclosure of which is incorporated herein by reference, to yield a fully hydroxylated surface, as follows.


The silica is heated at 850° C. for 3 days and then allowed to cool to ambient temperature (about 25° C.). The resulting material is suspended in 130 mL of water containing 200 ppm of HF. The suspension is boiled for 3 days, then allowed to cool to ambient temperature (about 25° C.). The cooled suspension is then filtered through an extra-fine fritted disk. The collected silica is washed with 2000 mL of deionized water. The silica is rinsed with acetone and dried at 120° C. and 0.1 mbar (0.01 kPa) for 15 hours. The dried silica is then rinsed successively with 300 mL of a water/ammonium hydroxide-solution (pH=9), rinsed with water to neutrality, and 100 mL of acetone and then dried at 0.1 mbar and 120° C. for 15 hours. The dried silica is kept in a dry nitrogen atmosphere until needed.


Step B: Preparation of a Stationary Phase Composition


To 15 grams of dried silica, prepared as in Step A, is added 110 mL of dry toluene under nitrogen. To this mixture is added 1.6 equivalents of imidazole, a first silane reagent according to a calculated stoichiometry, and a second silane reagent according to a calculated stoichiometry, wherein the stoichiometry is based on the calculated number of reactive silanol groups on the dried treated silica. The resulting mixture is heated at reflux temperature 110° C. for 24 hours, and then cooled to ambient temperature (about 25° C.). The product is collected by filtration The collected product is washed with 250 mL each of toluene, tetrahydrofuran, methanol and acetone and is then dried overnight (0.1 mbar, 110° C.).


Example 1

Preparation of a stationary phase composition comprising approximately 90% octadecyldimethylsilyl groups and approximately 10% tert-butyldimethylsilyl groups on the silica substrate.


The stationary phase composition was prepared according to General Procedure 1, Step B. 15 grams of silica were used. To this was added 11.99 grams (0.035 mol.) of octadecyldimethylchlorosilane, and 0.58 grams (0.004 mol.) of tert-butyldimethylchlorosilane.


Example 2

Preparation of a stationary phase composition comprising 80% octadecyldimethylsilyl groups and 20% tert- butyldimethylsilyl groups on the silica substrate.


The stationary phase composition was prepared according to General Procedure 1, Step B. 15 grams of silica were used. To this was added 10.73 grams (0.031 mol.) of octadecyldimethylchlorosilane, and 1.14 grams (0.008 mol.) of tert-butyldimethylchlorosilane.


Example 3

Preparation of a stationary phase composition comprising 50% octadecyldimethylsilyl groups and 50% ethyldimethylsilyl groups on the silica substrate.


The stationary phase composition was prepared according to General Procedure 1, Step B. 15 grams of silica were used. To this was added 6.66 grams (0.019 mol.) of octadecyldimethylchlorosilane, and 2.35 grams (0.019 mol.) of ethyldimethylchlorosilane.


Example 4

Preparation of a stationary phase composition comprising 40% octadecyldimethylsilyl groups and 60% ethyldimethylsilyl groups on the silica substrate.


The stationary phase composition was prepared according to General Procedure 1, Step B. 15 grams of silica were used. To this was added 5.33 grams (0.015 mol.) of octadecyldimethylchlorosilane, and 2.85 grams (0.023 mol.) of ethyldimethylchlorosilane.


Example 5

Preparation of a stationary phase composition comprising 50% octadecyldimethylsilyl groups and 50% propyldimethylsilyl groups on the silica substrate.


The stationary phase composition was prepared according to General Procedure 1, Step B. 15 grams of silica were used. To this was added 6.66 grams (0.019 mol.) of octadecyldimethylchlorosilane, and 2.62 grams (0.019 mol.) of propyldimethylchlorosilane.


Example 6

Preparation of a stationary phase composition comprising 40% octadecyldimethylsilyl groups and 60% propyldimethylsilyl groups on the silica substrate.


The stationary phase composition was prepared according to General Procedure 1, Step B. 15 grams of silica were used. To this was added 5.33 grams (0.015 mol.) of octadecyldimethylchlorosilane, and 3.15 grams (0.023 mol.) of propyldimethylchlorosilane.


ANALYTICAL

Table I shows carbon loading values obtained for chromatographic stationary phases prepared according to an embodiment of the invention. Duplicate values were determined for each sample. As can be seen from the data in Table I, the overall carbon loading decreases as the percentage of the shorter hydrocarbyl chain silyl group increases. This demonstrates that the method according to the invention is capable of producing chromatographic stationary phases having different ratios of silyl groups according to Formula I and Formula II bonded thereto.

TABLE IStationary Phase Composition% Carbon 10% C4:90% C1822.50-22.62 20% C4:80% C1821.02-20.89 30% C4:70% C1819.47-19.50 40% C4:60% C1818.35-18.40 50% C4:50% C1817.14-17.12100% C815.51-15.51 10% C4:90% C814.79-14.85 20% C4:80% C814.29-14.01 30% C4:70% C813.97-13.97 40% C4:60% C813.49-13.45 40% C1:60% C1818.81-16.85 50% C1:50% C1814.73-14.70 50% C3:50% C1816.24-16.29 60% C3:40% C1814.48-14.48 50% C2:50% C1815.07-15.06 60% C2:40% C1813.18-13.20


Tables II through VIII show the performance of various chromatographic stationary phases according to embodiments of the current invention, versus commercially available chromatographic stationary phases, both before and after an aqueous wash. The data demonstrate the superior performance of chromatographic stationary phases according to the current invention. Further, the data demonstrate that for each combination of silyl groups according to Formula I and Formula II there is an optimum ratio of the two silyl groups. The data also indicate that this optimum varies based on the combination of silyl groups according to Formula I and Formula II used. In addition, the optimum ratio of silyl groups according to Formula I and Formula II used is dependent upon the pore size of the substrate material. According to an embodiment of the invention, the larger the pore size for a porous material the higher the optimum loading of the silyl group according to Formula I versus the silyl group of Formula II.


Tables IX through XI show the stability of various commercially available chromatographic stationary phases and chromatographic stationary phases according to embodiments of the current invention. Stability runs were performed at a pH of 7. Stability was measured using k′ and peak symmetry.

TABLE IIXDB C18Scalar C18Luna C18Inertsil 2Inertsil 3RTK′RTK′RTK′RTK′RTK′Before Aqueous WashUracil1.5641.6851.7921.8421.94Procainamide2.6030.663.0780.833.230.82.8880.563.5820.85N-acetyl procainamide4.0211.584.9541.945.2111.914.3361.356.062.12N-propionyl procainamide7.0653.528.8514.269.1034.088.023.3511.4454.9Caffeine8.574.4810.9114.4811.2375.278.8973.8312.9585.68After Aqueous WashUracil1.1241.0231.7261.811.935Procainamide1.220.091.10.072.8270.642.6890.483.520.82N-acetyl procainamide1.3510.21.210.184.4511.583.9841.25.9472.07N-propionyl procainamide1.7420.551.5120.488.1633.737.6363.2211.3314.86Caffeine1.7420.551.7930.759.2674.367.9913.4212.6445.54Retention LossUracil28.1329939.287833.6830361.7372420.257732Procainamide53.13186.3636464.2625191.5662712.47678206.89058214.285711.7308773.529412N-acetyl procainamide66.4013987.3417775.5752990.7216514.5845317.277498.11808111.111111.8646862.358491N-propionyl procainamide75.3432484.37582.9171888.7323910.326278.5784314.788033.8805970.9960680.816327Caffeine79.6732887.7232183.5670483.2589317.5313717.2675510.1832110.704962.4232132.464789C18/C4Daiso AQSymmetery C184/6 Daiso 120RTK′RTK′RTK′Before AqueousWashUracil1.9981.6442.001Procainamide3.9520.982.50.523.6360.82N-acetyl6.8032.43.8171.326.222.11procainamideN-propionyl11.7714.897.5353.5810.514.26procainamideCaffeine14.796.417.7783.7313.1665.58After AqueousWashUracil1.9961.5262.001Procainamide3.8350.922.2090.443.5640.78N-acetyl6.5872.33.281.156.0842.04procainamideN-propionyl11.744.886.413.210.4894.24procainamideCaffeine14.1856.16.413.212.8145.4Retention LossUracil0.10017.1776160Procainamide2.9605266.12244911.6415.384621.9801984.878049N-acetyl3.175074.16666714.0686412.878792.1864953.317536procainamideN-propionyl0.2633590.20449914.9303310.614530.199810.469484procainamideCaffeine4.0906024.83619317.5880714.209122.6735533.225806














TABLE III













1244-79A
1244-79B
1244-81A
1244-81B
















RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
1.704

1.798

1.844

1.904



Procainamide
3.068
0.8
3.313
0.84
3.46
0.88
3.599
0.9


N-acetyl procainamide
4.952
1.9
5.426
2.02
5.756
2.12
6.04
2.18


N-propionyl procainamide
9.38
4.5
10.285
4.72
10.863
4.88
11.458
5.02


Caffeine
10.84
5.36
11.824
5.58
11.528
5.79
13.096
5.88


After Aqueous Wash


Uracil
1.364

1.69

1.78

1.884


Procainamide
1.981
0.45
2.87
0.7
3.132
0.76
3.406
0.8


N-acetyl procainamide
2.874
1.1
4.59
1.72
5.129
1.88
5.675
2.02


N-propionyl procainamide
5.557
3.07
8.784
4.2
9.872
4.54
11.102
4.89


Caffeine
5.557
3.07
9.673
4.72
10.911
5.13
12.188
5.47


Retention Loss


Uracil
19.95305

6.006674

3.470716

1.05042


Procainamide
35.43025
43.75
13.37157
16.66667
9.479769
13.63636
5.362601
11.11111


N-acetyl procainamide
41.96284
42.10526
15.4073
14.85149
10.89298
11.32075
6.043046
7.33945


N-propionyl procainamide
40.75693
31.77778
14.59407
11.01695
9.12271
6.967213
3.106999
2.589641


Caffeine
48.73616
42.72388
18.19181
15.41219
5.352186
11.39896
6.933415
6.972789



9/1 C18/C4

8/2 C18/C4

7/3 C18/C4

6/4 C18/C4



22.56 C

20.96

19.48

18.38



2.66 H

3.11

3.16

3.45

















1244-86A

1244-88C

1244-88D

















RT
K′
RT
K′
RT
K′







Before Aqueous Wash



Uracil
1.962

2.03

1.833




Procainamide
3.73
0.9
3.456
0.71
3.018
0.66



N-acetyl procainamide
6.447
2.28
5.164
1.54
4.69
1.57



N-propionyl
12.066
5.15
9.461
3.66
8.178
3.48



procainamide



Caffeine
14.12
6.19
10.694
4.27
10.15
4.55










C18 on Daiso 120A
C8 on Daiso 120A









After Aqueous Wash















Uracil
1.892

1.29

1.388




Procainamide
3.328
0.76
1.612
0.25
1.902
0.37



N-acetyl procainamide
5.65
1.99
2.01
0.57
2.587
0.86



N-propionyl
10.994
4.82
3.25
1.52
4.2
2.03



procainamide



Caffeine
12.107
5.4
3.25
1.52
4.723
2.4



Retention Loss



Uracil
3.567788

36.4532

24.27714



Procainamide
10.77748
15.55556
53.35648
64.78873
36.97813
43.93939



N-acetyl procainamide
12.36234
12.7193
61.07668
62.98701
44.84009
45.22293



N-propionyl
8.884469
6.407767
65.64845
58.46995
48.6427
41.66667



procainamide



Caffeine
14.25637
12.76252
69.60913
64.40281
53.46798
47.25275




5/5 C18/C4




17.13




3.28























TABLE IV













1244-82A
1244-82B
1244-83A
1244-81B



















RT
K′
RT
K′
RT
K′
RT
K′
RT
K′











Before Aqueous Wash

















Uracil
1.717

1.784

1.832

1.9

2.052



Procainamide
3.096
0.8
3.367
0.88
3.457
0.88
3.624
0.91
3.794
0.85


N-acetyl procainamide
5
1.92
5.577
2.12
5.78
2.16
5.988
2.16
6.514
2.18


N-propionyl
9.467
4.52
10.492
4.88
11.016
5.01
11.405
5
12.417
5.05


procainamide


Caffeine
10.96
5.38
12.388
5.94
12.775
5.98
13.001
5.84
14.118
5.88


After Aqueous Wash


Uracil
1.44

1.484

1.716

1.876

1.97


Procainamide
2.15
0.5
2.308
0.56
2.968
0.73
3.47
0.8
3.458
0.76


N-acetyl procainamide
3.198
1.24
3.536
1.38
4.884
1.82
5.46
1.95
5.868
1.98


N-propionyl
6.01
3.17
6.693
3.51
9.358
4.46
10.66
4.76
11.362
4.77


procainamide


Caffeine
3.62
3.42
7.196
3.84
10.314
5
11.686
5.32
12.503
5.32


Retention Loss


Uracil
16.13279

16.81614

6.331878

1.263158

3.996101


Procainamide
30.55556
37.5
31.45233
36.36364
14.14521
17.04545
4.249448
12.08791
8.856089
10.58824


N-acetyl procainamide
36.04
35.41667
36.59674
34.90566
15.50173
15.74074
8.817635
9.722222
9.917102
9.174312


N-propionyl
36.51632
29.86726
36.20854
28.07377
15.05084
10.97804
6.532223
4.8
8.496416
5.544554


procainamide


Caffeine
66.9708
36.43123
41.91153
35.35354
19.26419
16.38796
10.11461
8.90411
11.4393
9.52381



9/1 C18/C4

8/2 C18/C4

7/3 C18/C4

6/4

5/5



DMF

DMF

DMF

C18/C4

C18/C4









DMF

DMF





















TABLE V













1244-82A
1244-88A
1244-88B
1244-89A
















RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
1.932

1.97

2.026

2.029



Procainamide
3.275
0.7
3.298
0.68
3.419
0.68
3.346
0.65


N-acetyl procainamide
4.938
1.56
4.928
1.5
5.104
1.52
4.997
1.46


N-propionyl procainamide
9.156
3.74
9.189
3.67
9.481
3.68
9.432
3.65


Caffeine
10.318
4.34
10.22
4.18
10.57
4.22
10.282
4.06


After Aqueous Wash


Uracil
1.23

1.234

1.286

1.4


Procainamide
1.54
0.25
1.503
0.22
1.601
0.24
1.823
0.3


N-acetyl procainamide
1.937
0.58
1.834
0.48
1.995
0.55
2.373
0.7


N-propionyl procainamide
3.171
1.58
2.884
1.34
3.224
1.5
4.077
1.91


Caffeine
3.171
1.58
2.884
1.34
3.224
1.5
4.077
1.91


Retention Loss


Uracil
36.3354

37.36041

36.52517

31.00049


Procainamide
52.9771
64.28571
54.42693
67.64706
53.17344
64.70588
45.51704
53.84615


N-acetyl procainamide
60.77359
62.82051
62.78409
68
60.91301
63.81579
52.51151
52.05479


N-propionyl procainamide
65.36697
57.75401
68.61465
63.48774
65.99515
59.23913
56.77481
47.67123


Caffeine
69.2673
63.59447
71.78082
67.94258
69.49858
64.45498
60.34818
52.95567



C8

9/1 C8/C4

8/2 C8/C4

7/3 C8/C4



15.51

14.82

14.15

13.97



3.01

2.86

2.74

2.84
















1244-90A
1244-88D
1244-97a
1244-97b
1244-98b


















RT
K′
RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
2.054

1.833

2.168

2.185

2.206



Procainamide
3.43
0.67
3.018
0.66
3.835
0.76
3.755
0.72
3.864
0.76


N-acetyl procainamide
5.147
1.51
4.69
1.57
5.914
1.74
5.801
1.66
6.067
1.75


N-propionyl procainamide
9.562
3.66
8.178
3.48
10.683
3.92
10.593
3.84
10.884
3.94


Caffeine
10.545
4.13
10.15
4.55
11.912
4.5
11.63
4.32
12.074
4.47


After Aqueous Wash


Uracil
1.57

1.388

1.919

2.094

2.164


Procainamide
2.196
0.4
1.902
0.37
3.022
0.58
3.356
0.6
3.56
0.64


N-acetyl procainamide
3.02
0.92
2.587
0.86
4.511
1.35
5.098
1.43
5.533
1.56


N-propionyl procainamide
5.52
2.52
4.2
2.03
8.382
3.37
9.695
3.63
10.388
3.8


Caffeine
5.52
2.52
4.723
2.4
8.627
3.5
9.87
3.71
10.81
4


Retention Loss


Uracil
23.56378

24.27714

11.48524

4.16476

1.903898


Procainamide
35.97668
40.29851
36.97813
43.93939
21.19948
23.68421
10.62583
16.66667
7.867495
15.78947


N-acetyl procainamide
41.32504
39.07285
44.84009
45.22293
23.72337
22.41379
12.1186
13.85542
8.801714
10.85714


N-propionyl procainamide
42.27149
31.14754
48.6427
41.66667
21.53889
14.03061
8.477296
5.46875
4.557148
3.553299


Caffeine
47.65292
38.98305
53.46798
47.25275
27.57723
22.22222
15.13328
14.12037
10.46878
10.51454














6/4 C8/C4

C8 on Daiso 120A
6/4 C8/C1 hmds/tms
5/5 C8/C1 hmds/tms
4/6 C8/C1 hmds/tms



13.47

12.1



2.77

2.5
















1244-99B
1244-100B
1356-06a
1356-06b
1356-08a


















RT
K′
RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
2.239

2.254

2.037

2.05

2.082



Procainamide
3.758
0.68
3.874
0.72
3.674
0.8
3.641
0.78
3.548
0.7


N-acetyl procainamide
5.818
1.6
6.061
1.69
5.904
1.9
5.876
1.87
5.746
1.76


N-propionyl procainamide
10.578
3.7
10.522
3.67
10.622
4.24
10.576
4.16
10.626
4.1


Caffeine
11.272
4.04
11.678
4.18
12.254
5.02
12.026
4.87
11.508
4.53


After Aqueous Wash


Uracil
2.23

2.26

1.752

1.962

2.037


Procainamide
3.583
0.6
3.715
0.66
2.762
0.58
3.224
0.64
3.312
0.62


N-acetyl procainamide
5.503
1.47
5.84
1.58
4.241
1.42
5.122
1.61
5.314
1.61


N-propionyl procainamide
10.531
3.72
10.662
3.72
4.876
3.5
9.668
3.92
10.138
3.98


Caffeine
10.531
3.72
11.149
3.94
8.325
3.75
10.244
4.22
10.505
4.16


Retention Loss


Uracil
0.401965

−0.26619

13.99116

4.292683

2.161383


Procainamide
4.656732
11.76471
4.104285
8.333333
24.82308
27.5
11.4529
17.94872
6.651635
11.42857


N-acetyl procainamide
5.414232
8.125
3.646263
6.508876
28.16734
25.26316
12.83186
13.90374
7.518274
8.522727


N-propionyl procainamide
0.444318
−0.54054
−1.33055
−1.3624
54.09527
17.45283
8.585477
5.769231
4.592509
2.926829


Caffeine
6.573811
7.920792
4.529885
5.741627
32.063
25.2988
14.81789
13.34702
8.715676
8.16777













4/6 C8/C1 hmds/tms
3/7 C8/C1 hmds/tms
4/6 C8/C3 hmds/tms
3/7 C8/C3 hmds/tms
2/8 C8/C3 hmds/tms














1356-08b













RT
K′







Before Aqueous Wash



Uracil
2.094




Procainamide
3.65
0.74



N-acetyl procainamide
5.992
1.86



N-propionyl procainamide
10.56
4.04



Caffeine
11.929
4.7



After Aqueous Wash



Uracil
2.078



Procainamide
3.435
0.66



N-acetyl procainamide
5.6
1.69



N-propionyl procainamide
10.35
3.98



Caffeine
11.014
4.3



Retention Loss



Uracil
0.764088



Procainamide
5.890411
10.81081



N-acetyl procainamide
6.542056
9.139785



N-propionyl procainamide
1.988636
1.485149



Caffeine
7.670383
8.510638










1/9 C8/C3 hmds/tms






















TABLE VI













1244-90B
1244-93A
1244-93B
1244-94A
















RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
1.922



1.888

1.885



Procainamide
3.544
0.84


3.416
0.79
3.727
0.98


N-acetyl procainamide
5.827
2.04


5.813
2.08
6.353
2.37


N-propionyl
11.609
5.04


11.68
5.18
11.736
5.23


procainamide


Caffeine
12.674
5.59


13
5.89
14.18
6.52


After Aqueous Wash


Uracil
1.846



1.83

1.665


Procainamide
3.211
0.74


3.14
0.72
2.837
0.7


N-acetyl procainamide
5.21
1.82


5.215
1.85
4.68
1.75


N-propionyl
10.584
4.74


10.582
4.78
8.627
4.18


procainamide


Caffeine
11.117
5.02


11.19
5.12
9.662
4.8


Retention Loss


Uracil
3.954214



3.072034

11.67109


Procainamide
9.396163
11.90476


8.079625
8.860759
23.8798
28.57143


N-acetyl procainamide
10.58864
10.78431


10.28729
11.05769
26.33402
26.16034


N-propionyl
8.829357
5.952381


9.400685
7.722008
26.49114
20.07648


procainamide


Caffeine
12.28499
10.19678


13.92308
13.07301
31.86178
26.38037












70% C18 EC
85% C18 EC
55% C18 EC
7/3 C18/C4 hmds/tms
















1244-96A
1244-96B
1244-98A
1244-100A
















RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
1.942

1.98

2.04

2.097



Procainamide
4.048
1.08
3.702
0.87
3.85
0.89
3.916
0.86


N-acetyl procainamide
6.549
2.37
6.22
2.14
6.37
2.12
5.474
2.08


N-propionyl
11.8
5.08
11.873
5
11.723
4.74
11.712
4.58


procainamide


Caffeine
14.351
6.39
13.602
5.87
13.808
5.77
13.734
5.55


After Aqueous Wash


Uracil
1.751

1.894

1.932

1.981


Procainamide
3.201
0.83
3.283
0.74
3.346
0.74
3.387
0.71


N-acetyl procainamide
5.006
1.86
5.399
1.85
5.412
1.8
5.439
1.74


N-propionyl
9.278
4.3
10.608
4.6
10.298
4.33
10.234
4.16


procainamide


Caffeine
10.466
4.98
11.45
5.04
11.311
4.85
11.202
4.66


Retention Loss


Uracil
9.835221

4.343434

5.294118

5.531712


Procainamide
20.92391
23.14815
11.31821
14.94253
13.09091
16.85393
13.50868
17.44186


N-acetyl procainamide
23.56085
21.51899
13.19936
13.5514
15.03925
15.09434
0.639386
16.34615


N-propionyl
21.37288
15.35433
10.65443
8
12.15559
8.649789
12.61954
9.170306


procainamide


Caffeine
27.07128
22.06573
15.8212
14.13969
18.08372
15.94454
18.436
16.03604












6/4 C18/C4 hmds/tms
5/5 C18/C4 hmds/tms
4/6 C18/C4 hmds/tms
3/7 C18/C4 hmds/tms







1365-02a
1365-02b
1365-08a
1289-43
















RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
2.02

2.094

1.988

1.975



Procainamide
3.796
0.88
3.868
0.84
3.994
1.01
4.429
1.24


N-acetyl procainamide
6.389
2.16
6.469
2.09
7.199
2.62
8.484
3.3


N-propionyl
12.132
5
12.232
4.84
13.521
5.8
14.966
6.58


procainamide


Caffeine
14.008
5.93
13.675
5.53
15.942
7.02
15.919
8.83


After Aqueous Wash


Uracil
2.004

2.072

1.939

1.808


Procainamide
3.598
0.8
3.647
0.76
3.632
0.88
3.583
0.98


N-acetyl procainamide
5.999
1.99
6.055
1.92
6.462
2.33
6.659
2.68


N-propionyl
11.725
4.85
11.897
4.74
12.606
5.5
12.238
5.76


procainamide


Caffeine
12.775
5.37
12.67
5.12
14.078
6.26
14.783
7.18


Retention Loss


Uracil
0.792079

1.050621

2.464789

8.455696


Procainamide
5.216017
9.090909
5.713547
9.52381
9.063595
12.87129
19.10138
20.96774


N-acetyl procainamide
6.104242
7.87037
6.399753
8.133971
10.23753
11.0687
21.51108
18.78788


N-propionyl
3.354764
3
2.738718
2.066116
6.767251
5.172414
18.22798
12.46201


procainamide


Caffeine
8.802113
9.443508
7.349177
7.414105
11.69238
10.82621
7.136127
18.6863












5/5 C18/C3 hmds/tms
4/6 C18/C3 hmds/tms
5/5 C18/C3 hmds/tms
5/5 C18/C3 hmds/tms























TABLE VII













1244-99A
1356-01a
1356-01b
1244-96B
1244-98A


















RT
K′
RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
2.284

2.1

1.996

1.98

2.04



Procainamide
4.07
0.86
3.83
0.82
3.783
0.9
3.702
0.87
3.85
0.89


N-acetyl procainamide
6.922
2.17
6.484
2.09
6.399
2.2
6.22
2.14
6.37
2.12


N-propionyl procainamide
12.542
4.74
12.504
4.96
12.001
5.02
11.873
5
11.723
4.74


Caffeine
14.218
5.52
13.615
5.48
13.876
5.95
13.602
5.87
13.808
5.77


After Aqueous Wash


Uracil
2.18

2.087

1.932

1.894

1.932


Procainamide
3.823
0.76
3.66
0.76
3.417
0.76
3.283
0.74
3.346
0.74


N-acetyl procainamide
6.472
1.97
6.169
1.96
5.684
1.94
5.399
1.85
5.412
1.8


N-propionyl procainamide
12.446
4.71
11.296
4.89
11.038
4.72
10.608
4.6
10.298
4.33


Caffeine
13.147
5.04
12.862
5.16
11.973
5.2
11.45
5.04
11.311
4.85


Retention Loss


Uracil
4.553415

0.619048

3.206413

4.343434

5.294118


Procainamide
6.068796
11.62791
4.438642
7.317073
9.674861
15.55556
11.31821
14.94253
13.09091
16.85393


N-acetyl procainamide
6.501011
9.21659
4.858112
6.220096
11.17362
11.81818
13.19936
13.5514
15.03925
15.09434


N-propionyl procainamide
0.765428
0.632911
9.660909
1.41129
8.024331
5.976096
10.65443
8
12.15559
8.649789


Caffeine
7.532705
8.695652
5.530665
5.839416
13.71433
12.60504
15.8212
14.13969
18.08372
15.94454













4/6 C18/C1 hmds/tms
5/5 C18/C1 hmds/tms
6/4 C18/C1 hmds/tms
5/5 C18/C4 hmds/tms
4/6 C18/C4 hmds/tms




















1365-02a

1365-02b



1365-04b



















RT
K′
RT
K′
RT
K′
RT
K′







Before Aqueous Wash



Uracil
2.02

2.094

1.98

2.18




Procainamide
3.796
0.88
3.868
0.84
3.944
1
4.094
0.88



N-acetyl procainamide
6.389
2.16
6.469
2.09
7.255
2.66
7.234
2.32



N-propionyl procainamide
12.132
5
12.232
4.84
13.481
5.81
13.352
5.12



Caffeine
14.008
5.93
13.675
5.53
15.862
7.02
15.254
6



After Aqueous Wash



Uracil
2.004

2.072

1.963

2.174



Procainamide
3.598
0.8
3.647
0.76
3.692
0.88
3.903
0.8



N-acetyl procainamide
5.999
1.99
6.055
1.92
6.744
2.44
6.912
2.18



N-propionyl procainamide
11.725
4.85
11.897
4.74
13.135
5.69
13.319
5.12



Caffeine
12.775
5.37
12.67
5.12
14.58
6.43
14.364
5.61



Retention Loss



Uracil
0.792079

1.050621

0.858586

0.275229



Procainamide
5.216017
9.090909
5.713547
9.52381
6.389452
12
4.665364
9.090909



N-acetyl procainamide
6.104242
7.87037
6.399753
8.133971
7.043418
8.270677
4.451203
6.034483



N-propionyl procainamide
3.354764
3
2.738718
2.066116
2.566575
2.065404
0.247154
0



Caffeine
8.802113
9.443508
7.349177
7.414105
8.082209
8.404558
5.834535
6.5
















5/5 C18/C3 hmds/tms

4/6 C18/C3 hmds/tms

5/5 C18/C2 hmds/tms

4/6 C18/C2 hmds/tms


























TABLE VIII













AT1

SinochromB

SinochromA

1289-45



















RT
K′
RT
K′
RT
K′
RT
K′







Before Aqueous Wash



Uracil
1.652

1.851

1.928

1.982




Procainamide
3.14
0.9
2.946
0.62
3.726
0.93
4.214
1.12



N-acetyl procainamide
5.18
2.14
4.373
1.36
6.408
2.32
7.79
2.93



N-propionyl



procainamide
9.019
4.46
6.359
2.44
11.052
4.74
13.761
5.94



Caffeine
11.692
6.08
8.966
3.84
14.012
6.38
17.379
7.76



After Aqueous Wash



Uracil
1.004

1.822

1.858

1.905



Procainamide
1.061
0.06
2.9
0.59
3.45
0.86
3.709
0.95



N-acetyl procainamide
1.061
0.06
4.204
1.31
5.86
2.16
6.755
2.54



N-propionyl
1.208
0.2
6.07
2.33
10.128
4.45
12.558
5.59



procainamide



Caffeine
1.208
0.2
8.52
3.68
12.812
5.9
14.723
6.72



Retention Loss



Uracil
39.22518

1.566721

3.630705

3.884965



Procainamide
66.21019
93.33333
1.561439
4.83871
7.407407
7.526882
11.98386
15.17857



N-acetyl procainamide
79.51737
97.19626
3.864624
3.676471
8.55181
6.896552
13.28626
13.31058



N-propionyl
86.60605
95.5157
4.54474
4.508197
8.360478
6.118143
8.742097
5.892256



procainamide



Caffeine
89.66815
96.71053
4.974348
4.166667
8.564088
7.523511
15.28281
13.40206

















1289-46
1289-45
1289-49
1356-14
1356-15


















RT
K′
RT
K′
RT
K′
RT
K′
RT
K′





Before Aqueous Wash


Uracil
2.068

2.004

1.968

2.015

1.92


Procainamide
4.393
1.12
4.341
1.12
4.03
1.05
3.85
0.92
3.703
0.93


N-acetyl procainamide
7.908
2.83
7.887
1.12
7.224
2.97
6.747
2.35
6.36
2.32


N-propionyl procainamide
13.65
5.6
13.815
1.12
12.58
5.4
11.128
4.52
10.726
4.59


Caffeine
17.267
7.35
17.583
1.12
15.754
7
14.4
6.14
13.918
6.25


After Aqueous Wash


Uracil
1.96

1.86

1.939

2.011

1.91



Procainamide
3.741
0.9
3.602

3.719
0.92
3.734
0.86
3.585
0.88


N-acetyl procainamide
6.608
2.37
6.376

6.608
2.41
6.467
2.22
6.129
2.21


N-propionyl procainamide
12.146
5.2
11.694

12.074
5.22
11.068
4.5
10.584
4.53


Caffeine
14.101
6.19
13.825

14.215
6.36
13.714
5.82
13.324
5.98


Retention Loss


Uracil
5.222437

7.185629

1.473577

0.198511

0.520833


Procainamide
14.84179
19.64286
17.02373

7.717122
12.38095
3.012987
6.521739
3.186605
5.376344


N-acetyl procainamide
16.43905
16.25442
19.15811

8.527132
18.85522
4.149993
5.531915
3.632075
4.741379


N-propionyl procainamide
11.01832
7.142857
15.35288

4.022258
3.333333
0.53918
0.442478
1.323886
1.30719


Caffeine
18.33555
15.78231
21.37292

9.768948
9.142857
4.763889
5.211726
4.267855
4.32









HP treated

HF treated









5-5

7-3















W055703

W055702















RT
K′
RT
K′







Before Aqueous Wash



Uracil
1.97

1.826




Procainamide
3.652
0.86
3.209
0.76



N-acetyl procainamide
6.167
2.13
5.044
1.76



N-propionyl procainamide
10.028
4.09
8.434
3.62



Caffeine
12.968
5.58
10.78
4.9



After Aqueous Wash



Uracil
1.97

1.746



Procainamide
3.537
0.8
2.933
0.68



N-acetyl procainamide
5.954
2.02
4.53
1.59



N-propionyl procainamide
10.014
4.08
7.582
3.34



Caffeine
12.438
5.32
9.475
4.42



Retention Loss



Uracil
0

4.381161



Procainamide
3.148959
6.976744
8.60081
10.52632



N-acetyl procainamide
3.453867
5.164319
10.19033
9.659091



N-propionyl procainamide
0.139609
0.244499
10.10197
7.734807



Caffeine
4.086983
4.659498
12.10575
9.795918



Before Aqueous Wash




HF

HF




treated

treated




5-5

9-1






















TABLE IX













C18/C4 EC




Column
Scalar
C18/C4/EC 7/3
6/4DMF
C8/EC
Daiso C18 AQ

















Vol
K′
Symm.
K′
Symm.
K′
Symm.
K′
Symm.
K′
Symm.





  0
5.7
0.92
10.8
0.93
24.88
1.09
6.37
1.01
6.76
1.08


 480
5.72
0.91
10.5
0.96
24.62
1.09
6.26
1
6.58
1.08


 960
5.73
0.91
10.37
0.94
24.45
1.08
6.19
0.99
6.47
1.07


1440
5.7
0.92
9.53
0.95
23.5
1.06
5.93
1
6.4
1.07


1920
5.7
0.92
6.19
0.94
15.25
1.07
5.3
1
6.28
1.07


2880
5.69
0.91
3.3
0.92
5.38
1.03
3.76
1.09
6.19
1.65


3360
5.66
0.93
2.69
0.92
2.36
0.98
2.9
2.19
5.28
2.2


4320
5.6
0.57




2.8
1.75
3.31
1.92


4800
5.68
0.56




2.54
1.63
2.42
1.89


5280
4.17
0.69




2.51
1.22


5760
4.14
1.03


6240
3.92
0.77


6720
3.24
0.21


7200
3.22
0.59
















7/3 C18/C4
4/6 C18/C1



Column
70% C18 TMS EC
tms/hmds EC
tms/hmds EC
5/5C18/C4















Vol
K′
Symm.
K′
Symm.
K′
Symm.
K′
Symm.





  0
16.85
1.72
2.82
0.95
4.11
2.47
2.93
1.07


 480
16.54
1.65
2.75
0.96
4.04
2.15
2.73
1.05


 960
16.27
1.58
2.75
0.94
3.98
2.07
2.62
1.03


1440
14.5
1.26
2.74
0.94
3.91
1.81
2.51
1.04


1920
8.43
2.29
2.73
0.95
3.81
1.44
2.41
1.62


2880
4.96
2.64
2.72
0.95
3.73
1.32
2.28
1.51


3360
3.83
2.44
2.71
0.95
3.56
0.21
2.17
1.07


4320
3.17
1.91
2.7
0.96
3.67
0.5


4800
2.77
1.72
2.68
0.96


5280


2.67
0.97


5760


6240


6720


7200




















TABLE X











1244-
7/3 C18/C4
4/6 C18/C1



Column
98A
tms/hmds EC
tms/hmds EC
Daiso C18 AQ
















Vol
K′
Symm.
K′
Symm.
K′
Symm.
Symm.
K′
Symm.





  0
4.5
1.01
2.82
0.95
4.11

2.47
6.76
1.08


 480
4.43
1.03
2.75
0.96
4.04

2.15
6.58
1.08


 960
4.42
1.02
2.75
0.94
3.98

2.07
6.47
1.07


1440
4.38
1.02
2.74
0.94
3.91

1.81
6.4
1.07


1920
4.36
1.03
2.73
0.95
3.81

1.44
6.28
1.07


2880
4.33
1.04
2.72
0.95
3.73

1.32
6.19
1.65


3360
4.3
1.05
2.71
0.95
3.56

0.21
5.28
2.2


4320
4.3
1.29
2.7
0.96
3.67

0.5
3.31
1.92


4800
4.3
1.9
2.68
0.96



2.42
1.89


5280


2.67
0.97


5760


6240


6720


7200










6/4




C18/C4 EC




















4/6 C18/C3





Column
Inertsil3

tms/hmds EC

5/5C18/C4













Vol
K′
Symm.
K′
Symm.
K′
Symm.





  0
5.61
0.93
4.05
1.06
2.93
1.07


 480
5.54
0.92
3.95
1.07
2.73
1.05


 960
5.54
0.93
3.91
1.04
2.62
1.03


1440
5.52
0.92
3.87
1.04
2.51
1.04


1920
5.5
0.93
3.82
1.04
2.41
1.05


2880
5.48
0.93
3.78
1.31
2.28
1.62


3360
5.46
0.94
3.73
2.04
2.17
1.51


4320
5.43
0.94
3.66
2.26
2.08
1.07


4800
5.39
0.92
3.58
1.91


5280


3.48
1.42


5760


6240


6720


7200




















TABLE XI













4/6



Column
Scalar
Inertsil3
C18/C3 tms/hmds EC
Daiso C18 AQ















Vol
K′
Symm.
K′
Symm.
K′
Symm.
K′
Symm.


















0
5.7
0.92
5.61
0.93
4.05
1.06
6.76
1.08


480
5.72
0.91
5.54
0.92
3.95
1.07
6.58
1.08


960
5.73
0.91
5.54
0.93
3.91
1.04
6.47
1.07


1440
5.7
0.92
5.52
0.92
3.87
1.04
6.4
1.07


1920
5.7
0.92
5.5
0.93
3.82
1.04
6.28
1.07


2880
5.69
0.91
5.48
0.93
3.78
1.31
6.19
1.65


3360
5.66
0.93
5.46
0.94
3.73
2.04
5.28
2.2


4320
5.6
0.57
5.43
0.94
3.66
2.26
3.31
1.92


4800
5.68
0.56
5.39
0.92
3.58
1.91
2.42
1.89


5280
4.17
0.69


3.48
1.42


5760
4.14
1.03


6240
3.92
0.77


6720
3.24
0.21


7200
3.22
0.59








Claims
  • 1. A chromatographic stationary phase composition comprising a solid support having bonded thereto at least one silyl moiety according to Formula I:
  • 2. A method for producing a chromatographic stationary phase comprising reacting a solid support having reactive silanol groups thereon with a first silane compound according to Formula III:
Provisional Applications (1)
Number Date Country
60728407 Oct 2005 US